Stipple Bio

<cite index="3-1,17-2">Stipple Bio is a private biotechnology company founded in 2021</cite> and <cite index="3-2">headquartered in Cambridge, MA</cite>. <cite index="3-6,3-7">The company offers epitope-level resolution technology for single-cell profiling and allows the identification of novel therapeutic targets and the development of precision therapies, enabling users with therapies for a wide range of solid and hematologic malignancies</cite>. <cite index="11-1">Leveraging the Pointillist Platform, they uncover novel cancer target binding epitopes against known or novel targets that preferentially bind to tumor but not to healthy tissue</cite>, with applications to multiple modalities including antibody-drug conjugates (ADCs), T-cell engagers, and radiopharmaceuticals. <cite index="8-2">The company remains active</cite>, with two lead programs in development focused on cancer immunotherapy.